Nanobiotix S.A. American Depositary Shares (NBTX)
Stock · NASDAQ · Health Care
$21.3as of 10/16/2026
Price chart
Active signals
NBTX Signal Track Record
How signals performed across all stocks →What NBTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 27 | +5.3% | 63% | September 30, 2026 |
| Bollinger Band Breakout | 25 | -3.5% | 44% | August 17, 2026 |
| Bollinger Band Breakdown | 17 | +6.7% | 59% | October 1, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -4.7% | 50% | September 18, 2026 |
| Any 20-session window (baseline) | +1.5% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NBTX
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 98
- Website
- www.nanobiotix.com
Fundamentals
- 1-day range
- $21.22$23.11
- Market cap
- $1.83B
- P/E (trailing)
- —
- P/E (forward)
- -128.49
- EPS (trailing)
- $-0.50
- Dividend yield
- —
- Beta
- -0.54
- Avg. volume
- 150.8K
Forecasts
3 analyst ratings
Nanobiotix S.A. American Depositary Shares Competitors
Chosen by industry and closest market cap.
- NBTXNanobiotix S.A. American Depositary Shares$21.3▼ 4.18%Market cap $1.83BP/E —$13.1$47.66
- CMPSCOMPASS Pathways Plc American Depository Shares$10.75▼ 7.49%Market cap $1.83BP/E —$4.88$15.87
- DMRADamora Therapeutics Inc. Ordinary Shares$18.44▼ 1.60%Market cap $1.84BP/E —$16.5$34.89
- BCAXBicara Therapeutics Inc. Common Stock$16.78▼ 4.77%Market cap $1.81BP/E —$13.7$30.99
- ANIPANI Pharmaceuticals Inc.$72.29▲ 0.01%Market cap $1.86BP/E 15.16$69.58$97
- NAMSWNewAmsterdam Pharma Company N.V. Warrant$9▼ 17.81%Market cap $1.87BP/E —$9.79$30.45
- KARDKardigan Inc. Common Stock$13.03▼ 6.12%Market cap $1.79BP/E —$12.23$27
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NBTX Nanobiotix S.A. American Depositary Shares | $1.83B | — | $21.3 | ▼ 4.18% | $13.1$47.66 |
| CMPS COMPASS Pathways Plc American Depository Shares | $1.83B | — | $10.75 | ▼ 7.49% | $4.88$15.87 |
| DMRA Damora Therapeutics Inc. Ordinary Shares | $1.84B | — | $18.44 | ▼ 1.60% | $16.5$34.89 |
| BCAX Bicara Therapeutics Inc. Common Stock | $1.81B | — | $16.78 | ▼ 4.77% | $13.7$30.99 |
| ANIP ANI Pharmaceuticals Inc. | $1.86B | 15.16 | $72.29 | ▲ 0.01% | $69.58$97 |
| NAMSW NewAmsterdam Pharma Company N.V. Warrant | $1.87B | — | $9 | ▼ 17.81% | $9.79$30.45 |
| KARD Kardigan Inc. Common Stock | $1.79B | — | $13.03 | ▼ 6.12% | $12.23$27 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial OfficerYahoo · 10/1/2026
- Can J&J’s Partnership Drive More Upside for Nanobiotix?Yahoo · 9/28/2026
- NANOBIOTIX Provides First Half 2026 Operational and Financial UpdateYahoo · 9/24/2026
- Nanobiotix H1 EPS $(0.82) Down From $(0.12) YoY, Sales $6.533M Down From $30.202M YoYBenzinga · 9/24/2026
- Voting Rights and Shares Capital of the CompanyYahoo · 9/22/2026
- Nanobiotix (NBTX): Can Lung Tumor Control Justify Repeat Radiation Risks?Yahoo · 9/17/2026
- Guggenheim Assumes Nanobiotix at Buy, Announces Price Target of $64Benzinga · 9/15/2026
- NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung CancerYahoo · 9/14/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 5.70M
- Total value held
- $175.90M
- Institutional holders
- 15
- Unknown5.62M
- Unknown36.3K
- Unknown13.5K
- Unknown9.2K
- Unknown5.6K
- Unknown3.6K
- Unknown2.3K
- Unknown1.8K
- Unknown828
- Unknown514
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
NBTX May Be 59% Undervalued After CFO Change
Nanobiotix’s recent CFO change has led analysts to suggest the shares could be undervalued by about 59%. The stock is currently near its 12‑touch support level of $34.40 and below the average target of $53.86. With a 52‑week range of $13.10 to $47.66, the current price sits closer to the lower end, supporting the undervaluation view.
NBTX May Be 59% Undervalued After CFO Change. Nanobiotix’s recent CFO change has led analysts to suggest the shares could be undervalued by about 59%. The stock is currently near its 12‑touch support level of $34.40 and below the average target of $53.86. With a 52‑week range of $13.10 to $47.66, the current price sits closer to the lower end, supporting the undervaluation view.